New schizophrenia drug shows promise in early trial
NCT ID NCT00862992
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested three different doses of MP-214 (cariprazine) in 34 adults with schizophrenia. The goal was to check safety, how the drug moves through the body, and whether it helps control symptoms. Participants took the drug once daily for 14 days, starting low and increasing to a fixed dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cariprazine (MP-214)
- What this could lead to
- If successful, this could lead to a new oral medication option for managing schizophrenia symptoms.
- What could go wrong
- This is a small, early-phase study with only 34 participants and short 14-day treatment. Results may not apply to all patients, and side effects are still being identified.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hoyu Hospital
Kure, Hiroshima, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?